Key facts
- This page summarizes Wallace L. Hall Jr.'s Form 4/A - Amendment filing for Tvardi Therapeutics, Inc. (TVRD).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 May 2025, 18:19.
Wallace L. Hall Jr. - 15 Apr 2025 Form 4/A - Amendment Insider Report for Tvardi Therapeutics, Inc. (TVRD)
- Reporting relationship
- Director
- Issuer ticker
- TVRD
- Reported as of
- 15 Apr 2025
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 02 May 2025, 18:19:16 UTC
- Original report date
- 17 Apr 2025
- Next SEC filing
- 21 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dan Conn, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Wallace L. Hall Jr. filed Form 4/A - Amendment for Tvardi Therapeutics, Inc. (TVRD) on 02 May 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reporting Owners (1)
CIK 0001762801
Primary reporting owner
HALL WALLACE L JR
- Relationship
- Director
- Address
- C/O TVARDI THERAPEUTICS, INC., 3 SUGAR CREEK CTR BLVD, STE 525, SUGAR LAND
- Signature
- /s/ Dan Conn, Attorney-in-Fact
- Signature date
- 02 May 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TVRD
transaction
Common Stock
Award
- Transaction value
- Shares
- +44,712
- Change %
- Price
- Shares after
- 44,712
- Date
- 15 Apr 2025
- Ownership
- Firepit Partners, LP
- Footnotes
- F1, F2, F3, F4
TVRD
transaction
Common Stock
Award
- Transaction value
- Shares
- +202,044
- Change %
- Price
- Shares after
- 202,044
- Date
- 15 Apr 2025
- Ownership
- BioMatrix Partners Ltd.
- Footnotes
- F1, F2, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The initial Form 4 inadvertently listed an incorrect transaction code.
Footnote F2
Received in exchange for 250,000 shares of Series A Preferred Stock of Tvardi Therapeutics, Inc. ("Legacy Tvardi") pursuant to Agreement and Plan of Merger and Reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub") and Legacy Tvardi, as amended (the "Merger Agreement") and 11,183 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $250,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes.
Footnote F3
Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc.
Footnote F4
The Reporting Person is a general partner of Firepit Partners, LP ("Firepit") and may be deemed to share voting and dispositive power of the shares held by Firepit but disclaims beneficial ownership of the shares held by such entity except to any pecuniary interest therein.
Footnote F5
Received in exchange for 1,000,000 shares of Series A Preferred Stock and 173,448 Series B Preferred Stock of Legacy Tvardi pursuant to the Merger Agreement and 44,665 shares of common stock of Issuer issuable upon exchange of convertible notes of Tvardi in the principal amount of $1,000,000 plus accrued and unpaid interest, pursuant to the Merger Agreement and the terms of the convertible notes.
Footnote F6
The Reporting Person is a general partner of BioMatrix Partners Ltd. ("BioMartix") and may be deemed to share voting and dispositive power of the shares held by Biomatrix but disclaims beneficial ownership of the shares held by such entity except to any pecuniary interest therein.